The New Cancer Study They Can't Ignore. And Why It Only Tells Half the Story

In March 2026, something unusual happened in cancer research.

A team of physicians, led by Dr. Peter McCullough, one of the most cited cardiologists in medical history, submitted a study to peer review that quietly demolished one of oncology's most stubborn assumptions.

The assumption: that repurposed antiparasitic drugs have no role in cancer treatment.

The study: 122 cancer patients. Six months of follow-up. The kind of results that don't come from supplements.

Let that sink in.

The standard of care in late-stage cancer — platinum-based chemotherapy, achieves clinical benefit in roughly 30-50% of patients, depending on cancer type. At a cost of $12,000 to $30,000 per treatment cycle.

The protocol in this study costs less than $350 for a month's supply.

Why This Study Is Different

I've been following the research on repurposed drugs and cancer for several years. The Joe Tippens case. The South Korean case series. The thousands of patients quietly piecing together their own protocols in Facebook groups, comparing notes in real time.

What those cases lacked was structured data.

This study changes that. 197 cancer patients prescribed ivermectin (25mg) and mebendazole (250mg) through licensed U.S. physicians. Six months of follow-up. Self-reported outcomes published on Zenodo, a research repository operated by CERN, currently undergoing peer review.

And critically: the researchers noted what the patients were doing alongside the medication.

The patients who responded best were not just taking two compounds.

They were running a protocol.

What the Study Doesn't Tell You

The researchers noted something specific about the 48.4% who reported tumor shrinkage or no evidence of disease: they were combining ivermectin and mebendazole with nutritional interventions and additional compounds that targeted cancer metabolism from multiple directions simultaneously.

This is not coincidence. This is mechanism.

Cancer exploits twelve distinct metabolic pathways.

Fenbendazole disrupts microtubule formation, blocks glucose uptake, and induces apoptosis through multiple pathways simultaneously. Ivermectin inhibits glutamine metabolism and has selective pro-oxidant effects in cancer cells while leaving healthy cells unharmed. These are powerful compounds. The study confirms what thousands of patients already knew.

That covers two pathways.

The metabolic terrain that allows cancer to grow: dysfunctional mitochondria, glucose dependency, iron hijacking, galectin-3-driven metastatic spread. None of it is addressed by two compounds alone.

This is exactly why patients in the study who were also taking Vitamin D, curcumin, and immune-supporting mushrooms had the strongest outcomes.

The 13-Pathway Approach

Three years before this study was published, a team of integrative researchers built what the Facebook forums had been trying to assemble for years. Not a two-compound stack. Not a random supplement pile. A structured, synergistic, 30-day protocol targeting every known metabolic vulnerability in cancer simultaneously.

What 3,000+ Patients Have Reported

The Honest Conversation

The Genesis Protocol is not a proven cure.

Neither is the TWC ivermectin/mebendazole combination. The researchers said so themselves. The study is observational. The clinical trials haven't happened. The peer review is ongoing.

What is true: the biology is sound. The mechanisms are published. The compounds have established safety profiles from decades of human use. And the patients achieving the strongest outcomes — in the TWC study and everywhere else — were the ones running comprehensive protocols, not single compounds.

Every day spent piecing this together from forum threads is a day you're not on the full protocol. The Genesis Protocol exists so you don't have to spend 200 hours doing what took researchers months to build.